{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:58:25Z","timestamp":1793073505977,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejogrb.2025.114018","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T02:23:07Z","timestamp":1746757387000},"page":"114018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Model for the prediction of therapeutic failures of the 52\u00a0mg levonorgestrel intrauterine device"],"prefix":"10.1016","volume":"311","author":[{"given":"Alex","family":"Pujol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Casta\u00f1eda-Vozmediano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bord\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejogrb.2025.114018_b0005","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","article-title":"Effectiveness of long-acting reversible contraception","volume":"366","author":"Winner","year":"2012","journal-title":"N Engl J Med,"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114018_b0010","first-page":"345","article-title":"Management of women with abnormal uterine bleeding: Clinical practice guidelines of the French National College of Gynecologists and Obstetricians (CNGOF)","volume":"50","author":"Brun","year":"2022","journal-title":"Gynecol Obstet Fertil Senol,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0015","unstructured":"London: National Institute for Health and Care Excellence (NICE), Heavy menstrual bleeding: assessment and management. 2021."},{"key":"10.1016\/j.ejogrb.2025.114018_b0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bpobgyn.2015.11.012","article-title":"Abnormal uterine bleeding","volume":"34","author":"Whitaker","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol,"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114018_b0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ogrm.2018.06.004","article-title":"Heavy menstrual bleeding","volume":"28","author":"Chodankar","year":"2018","journal-title":"Obstet Gynaecol Reprod Med,"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2105\/AJPH.86.2.195","article-title":"Chronic gynecological conditions reported by US women: Findings from the National Health Interview Survey, 1984 to 1992","volume":"86","author":"Kjerulff","year":"1996","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114018_b0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1524-4733.2007.00168.x","article-title":"A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding","volume":"10","author":"Liu","year":"2007","journal-title":"Value Heal,"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1586\/17474108.4.2.179","article-title":"Health-related quality of life and economic burden of abnormal uterine bleeding","volume":"4","author":"Fraser","year":"2009","journal-title":"Expert Rev Obstet Gynecol,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0045","doi-asserted-by":"crossref","unstructured":"A. L. Lunardi Rocha, M. Cristina Fran\u00e7a Ferreira, R. Mara Lamaita, E. Batista C\u00e2ndido, M. Mendon\u00e7a Carneiro, and A. Lopes da Silva-Filho, \u201cHeavy menstrual bleeding: a global survey of health care practitioners\u2019 perceptions,\u201d Eur J Contracept Reprod Heal Care, vol. 23, no. 4, pp. 288\u2013294, 2018, doi: 10.1080\/13625187.2018.1483018.","DOI":"10.1080\/13625187.2018.1483018"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114018_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynecol Obstet,"},{"issue":"October","key":"10.1016\/j.ejogrb.2025.114018_b0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years\u00a0: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynecol Obs,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0060","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0049-3848(17)30072-5","article-title":"Heavy menstrual bleeding: an update on management","volume":"151","author":"Davies","year":"2017","journal-title":"Thromb Res,"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114018_b0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ogc.2016.04.002","article-title":"Management of Abnormal Uterine Bleeding with Emphasis on Alternatives to Hysterectomy","volume":"43","author":"Billow","year":"2016","journal-title":"Obstet Gynecol Clin North Am,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0070","doi-asserted-by":"crossref","unstructured":"J. Marjoribanks, \u201cSurgery versus medical therapy for heavy menstrual bleeding,\u201d Cochrane Database Syst. Rev., no. 1, 2016, doi: 10.1002\/14651858.cd003855.pub2.","DOI":"10.1002\/14651858.CD003855.pub3"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114018_b0075","first-page":"601","article-title":"Levonorgestrel-releasing intrauterine system for endometrial hyperplasia","volume":"2020","author":"Mittermeier","year":"2020","journal-title":"Cochrane Database Syst Rev,"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114018_b0080","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/humupd\/dmv023","article-title":"Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods","volume":"21","author":"Bahamondes","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2025.114018_b0085","first-page":"2020","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy)","volume":"11","author":"Sangkomkamhang","year":"2020","journal-title":"Cochrane Database Syst Rev,"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114018_b0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","article-title":"A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena","volume":"97","author":"Gemzell-Danielsson","year":"2012","journal-title":"Fertil Steril,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0095","doi-asserted-by":"crossref","unstructured":"C. KM, N. AT, T. NK, and E. Al., \u201cU.S. Selected Practice Recommendations for Contraceptive Use, 2024,\u201d MMWR Recomm Rep. 2024, vol. 73, no. 3, pp. 1\u201377, 2024.","DOI":"10.15585\/mmwr.rr7303a1"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ijgo.13998","article-title":"Expulsion and continuation rates of the levonorgestrel 52mg intrauterine system was similar among nulligravid and parous users","volume":"158","author":"Brull","year":"2022","journal-title":"Int J Gynecol Obstet,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0105","unstructured":"F. of S. & R. H. (FSRH), \u201cIntrauterine Contraception,\u201d Fac. Sex. Reprod. Healthc. Clin. Guid. RCOG., vol. 2015, no. September, pp. 1\u201352, 2019."},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1515\/HMBCI.2011.002","article-title":"A new concept of endometriosis and adenomyosis: Tissue injury and repair (TIAR)","volume":"5","author":"Leyendecker","year":"2011","journal-title":"Horm Mol Biol Clin Investig,"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1056\/NEJMoa1204724","article-title":"Levonorgestrel intrauterine system versus medical therapy for menorrhagia","volume":"368","author":"Gupta","year":"2013","journal-title":"N Engl J Med,"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114018_b0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/AOG.0000000000003034","article-title":"Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System","volume":"133","author":"Teal","year":"2019","journal-title":"Obstet Gynecol,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0125","first-page":"2020","article-title":"Progestogen-releasing intrauterine systems for heavy menstrual bleeding","volume":"6","author":"Bofill Rodriguez","year":"2020","journal-title":"Cochrane Database Syst Rev,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0130","unstructured":"J. Cohen, Statistical Power Analysis for the Behavioral Sciences. 1988."},{"key":"10.1016\/j.ejogrb.2025.114018_b0135","doi-asserted-by":"crossref","unstructured":"R. L. Sapra, S. Saluja, \u201cUnderstanding statistical association and correlation,\u201d Curr. Med. Res. Pract., vol. 11, no. 1, 2021, [Online]. Available: https:\/\/journals.lww.com\/cmre\/fulltext\/2021\/11010\/understanding_statistical_association_and.7.aspx.","DOI":"10.4103\/cmrp.cmrp_62_20"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114018_b0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human participants","volume":"333","author":"Association","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejogrb.2025.114018_b0145","doi-asserted-by":"crossref","unstructured":"V. Jain and H. O. D. Critchley, \u201cUterine bleeding: how understanding endometrial physiology underpins menstrual health,\u201d Nat Rev Endocrinol, vol. 18, no. 5. Nature Research, pp. 290\u2013308, May 01, 2022, doi: 10.1038\/s41574-021-00629-4.","DOI":"10.1038\/s41574-021-00629-4"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114018_b0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/AOG.0000000000000144","article-title":"Effects of age, parity, and device type on complications and discontinuation of intrauterine devices","volume":"123","author":"Aoun","year":"2014","journal-title":"Obstet Gynecol,"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114018_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.12.268","article-title":"Experience with same-day placement of the 52 mg levonorgestrel-releasing intrauterine system","volume":"222","author":"Casta\u00f1o","year":"2020","journal-title":"Am J Obstet Gynecol,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/AOG.0000000000005000","article-title":"Demographic, reproductive, and medical risk factors for intrauterine device expulsion","volume":"140","author":"Anthony","year":"2022","journal-title":"Obstet Gynecol Surv,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0165","article-title":"Expulsion rates of the levonorgestrel 52 mg intrauterine system are similar among women with heavy menstrual bleeding and users for contraception","author":"Furlani","year":"2021","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114018_b0170","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/01443610020001521","article-title":"Treatment of menorrhagia with the levonorgestrel intrauterine system: can we learn from our failures?","volume":"20","author":"Ikomi","year":"2000","journal-title":"J Obstet Gynaecol (Lahore)"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/OGX.0000000000000155","article-title":"Medical management of heavy menstrual bleeding: a comprehensive review of the literature","volume":"70","author":"Bitzer","year":"2015","journal-title":"Obstet Gynecol Surv,"},{"key":"10.1016\/j.ejogrb.2025.114018_b0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bpobgyn.2017.09.007","article-title":"Medical therapy for fibroids: An overview","volume":"46","author":"Sinai Talaulikar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol,"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114018_b0185","first-page":"449","article-title":"Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg","volume":"24","author":"Teunissen","year":"2019","journal-title":"Eur J Contracept Reprod Heal Care"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114018_b0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The Management of Uterine Leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J Obstet Gynaecol Canada"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525002945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525002945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:47:15Z","timestamp":1774928835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525002945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"alternative-id":["S0301211525002945"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114018","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model for the prediction of therapeutic failures of the 52\u00a0mg levonorgestrel intrauterine device","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114018"}}